179 related articles for article (PubMed ID: 29870791)
1. Advances in treatment formulations for acute myeloid leukemia.
Briot T; Roger E; Thépot S; Lagarce F
Drug Discov Today; 2018 Dec; 23(12):1936-1949. PubMed ID: 29870791
[TBL] [Abstract][Full Text] [Related]
2. The role of targeted therapy in the management of patients with AML.
Perl AE
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):54-65. PubMed ID: 29222237
[TBL] [Abstract][Full Text] [Related]
3. Daunorubicin-cytarabine liposome (CPX-351) in the management of newly diagnosed secondary AML: A new twist on an old cocktail.
Maakaron JE; Mims AS
Best Pract Res Clin Haematol; 2019 Jun; 32(2):127-133. PubMed ID: 31203994
[TBL] [Abstract][Full Text] [Related]
4. Evolving Therapies in Acute Myeloid Leukemia: Progress at Last?
DeAngelo DJ; Stein EM; Ravandi F
Am Soc Clin Oncol Educ Book; 2016; 35():e302-12. PubMed ID: 27249736
[TBL] [Abstract][Full Text] [Related]
5. [Incorporation of novel agents into the treatment for acute myeloid leukemia].
Yamauchi T
Rinsho Ketsueki; 2018; 59(10):1988-1996. PubMed ID: 30305501
[TBL] [Abstract][Full Text] [Related]
6. Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review.
Megías-Vericat JE; Martínez-Cuadrón D; Sanz MÁ; Poveda JL; Montesinos P
Expert Rev Clin Pharmacol; 2019 Mar; 12(3):197-218. PubMed ID: 30672340
[TBL] [Abstract][Full Text] [Related]
7. Are adjuncts to induction chemotherapy worthwhile in the treatment of acute myeloid leukemia?
Ravandi F
Best Pract Res Clin Haematol; 2014; 27(3-4):241-6. PubMed ID: 25455273
[TBL] [Abstract][Full Text] [Related]
8. CPX-351: changing the landscape of treatment for patients with secondary acute myeloid leukemia.
Talati C; Lancet JE
Future Oncol; 2018 May; 14(12):1147-1154. PubMed ID: 29378418
[TBL] [Abstract][Full Text] [Related]
9. New Food and Drug Administration-Approved and Emerging Novel Treatment Options for Acute Myeloid Leukemia.
Click ZR; Seddon AN; Bae YR; Fisher JD; Ogunniyi A
Pharmacotherapy; 2018 Nov; 38(11):1143-1154. PubMed ID: 30220082
[TBL] [Abstract][Full Text] [Related]
10. Induction therapy in acute myeloid leukemia: intensifying and targeting the approach.
Fernandez HF; Rowe JM
Curr Opin Hematol; 2010 Mar; 17(2):79-84. PubMed ID: 20087177
[TBL] [Abstract][Full Text] [Related]
11. [Novel therapies for acute myeloid leukemia based on genomic aberrations].
Umezawa Y; Kawamata N
Rinsho Ketsueki; 2019; 60(6):594-599. PubMed ID: 31281150
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the impact of single-nucleotide polymorphisms on treatment response, survival and toxicity with cytarabine and anthracyclines in patients with acute myeloid leukaemia: a systematic review protocol.
Puty TC; Sarraf JS; Do Carmo Almeida TC; Filho VCB; de Carvalho LEW; Fonseca FLA; Adami F
Syst Rev; 2019 May; 8(1):109. PubMed ID: 31053175
[TBL] [Abstract][Full Text] [Related]
13. Current and emerging therapies for acute myeloid leukemia.
Robak T; Wierzbowska A
Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
[TBL] [Abstract][Full Text] [Related]
14. Older Adults With Newly Diagnosed AML: Hot Topics for the Practicing Clinician.
Lai C; Bhansali RS; Kuo EJ; Mannis G; Lin RJ
Am Soc Clin Oncol Educ Book; 2023 May; 43():e390018. PubMed ID: 37155946
[TBL] [Abstract][Full Text] [Related]
15. A User's Guide to Novel Therapies for Acute Myeloid Leukemia.
Patel SA; Gerber JM
Clin Lymphoma Myeloma Leuk; 2020 May; 20(5):277-288. PubMed ID: 32113891
[TBL] [Abstract][Full Text] [Related]
16. Cytarabine and daunorubicin for the treatment of acute myeloid leukemia.
Murphy T; Yee KWL
Expert Opin Pharmacother; 2017 Nov; 18(16):1765-1780. PubMed ID: 29017371
[TBL] [Abstract][Full Text] [Related]
17. The fludarabine, cytarabine, and granulocyte colony-stimulating factor (FLAG) chemotherapy regimen is an alternative to anthracycline-based therapy for the treatment of acute myeloid leukemia for patients with pre-existing cardiac disease.
Saini L; Brandwein J; Turner R; Larratt L; Hamilton M; Peters A; Wu C; Zhu N; Patterson JM; Bolster L; Mant M; Ritchie B; Liew E; Ghosh S; Sandhu I
Eur J Haematol; 2016 Nov; 97(5):471-478. PubMed ID: 27028202
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia.
Megias-Vericat JE; Martinez-Cuadron D; Herrero MJ; Alino SF; Poveda JL; Sanz MA; Montesinos P
Curr Drug Metab; 2018; 19(1):55-74. PubMed ID: 29090664
[TBL] [Abstract][Full Text] [Related]
19. Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
Seymour JF; Döhner H; Butrym A; Wierzbowska A; Selleslag D; Jang JH; Kumar R; Cavenagh J; Schuh AC; Candoni A; Récher C; Sandhu I; Del Castillo TB; Al-Ali HK; Falantes J; Stone RM; Minden MD; Weaver J; Songer S; Beach CL; Dombret H
BMC Cancer; 2017 Dec; 17(1):852. PubMed ID: 29241450
[TBL] [Abstract][Full Text] [Related]
20. New agents in acute myeloid leukemia: beyond cytarabine and anthracyclines.
Fathi AT; Karp JE
Curr Oncol Rep; 2009 Sep; 11(5):346-52. PubMed ID: 19679009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
